For investors

Biotica Bio supports investment and portfolio teams with evidence-led due diligence and strategy.

What we offer

• Target due diligence — Structured assessment of biology, disease association, druggability, and safety so you can move at deal speed without sacrificing rigour.
• Pipeline and portfolio review — Prioritisation and evidence context across targets or indications for portfolio decisions.
• New area screening — Fast, reproducible scans of therapeutic areas or target classes using the same Open Targets evidence base.
• Reproducibility — Same query, same data; you can re-run or audit as evidence updates or share methodology with co-investors.
• No conflict — We do not invest; our only deliverable is the assessment and narrative.

The Open Targets Platform aggregates and scores target–disease evidence from dozens of curated and experimental sources—the same data that supports target validation across industry and academia. We turn that into decision-ready output for your process.